<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 15-month-old boy with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> developed <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>) after allogeneic bone marrow transplantation (BMT), in which the preparative regimen included 50 mg/kg/day <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and anti-lymphocyte globulin for 4 consecutive days </plain></SENT>
<SENT sid="1" pm="."><plain>The diagnosis was made based on clinical symptoms and data including, <z:hpo ids='HP_0002240'>hepatomegaly</z:hpo>, right upper quadrant <z:hpo ids='HP_0002027'>abdominal pain</z:hpo>, <z:hpo ids='HP_0000952'>jaundice</z:hpo>, <z:hpo ids='HP_0001541'>ascites</z:hpo>, <z:hpo ids='HP_0003256'>coagulopathy</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> which was refractory to transfusions of platelet concentrate </plain></SENT>
<SENT sid="2" pm="."><plain>We gave 2, 3, 5 and 5 mg/day/body of recombinant tissue plasminogen activator (tPA) followed by <z:chebi fb="5" ids="28304">heparin</z:chebi> and <z:chebi fb="0" ids="15544">prostaglandin E1</z:chebi> (<z:chebi fb="0" ids="15544">PGE1</z:chebi>) effectively and without significant side effect on days 9, 10, 13 and 14, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical and biochemical improvement was steady and dramatic </plain></SENT>
<SENT sid="4" pm="."><plain>We suggest that tPA following continuous <z:chebi fb="5" ids="28304">heparin</z:chebi> and <z:chebi fb="0" ids="15544">PGE1</z:chebi> infusion may be useful in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> even in infantile cases </plain></SENT>
</text></document>